Ovarian cancer (OvCa) metastasizes to organs in the abdominal cavity, such as the omentum, which are covered by a single layer of mesothelial cells. Mesothelial cells are generally thought to be "bystanders" to the metastatic process and simply displaced by OvCa cells to access the submesothelial extracellular matrix. Here, using organotypic 3D cultures, we found that primary human mesothelial cells secrete fibronectin in the presence of OvCa cells. Moreover, we evaluated the tumor stroma of 108 human omental metastases and determined that fibronectin was consistently overexpressed in these patients. Blocking fibronectin production in primary mesothelial cells in vitro or in murine models, either genetically (fibronectin 1 floxed mouse model) or via siRNA, decreased adhesion, invasion, proliferation, and metastasis of OvCa cells. Using a coculture model, we determined that OvCa cells secrete TGF-b1, which in turn activates a TGF-b receptor/RAC1/SMADdependent signaling pathway in the mesothelial cells that promotes a mesenchymal phenotype and transcriptional upregulation of fibronectin. Additionally, blocking a 5 or b 1 integrin function with antibodies reduced metastasis in an orthotopic preclinical model of OvCa metastasis. These findings indicate that cancer-associated mesothelial cells promote colonization during the initial steps of OvCa metastasis and suggest that mesothelial cells actively contribute to metastasis.
Introduction
The biology of serous high-grade ovarian cancer (OvCa) is different from that of most other solid tumors, since OvCa is predominantly confined within the abdominal and pleural cavities and rarely metastasizes hematogenously (1) . Moreover, OvCa is generally only superficially invasive, although advanced disease is characterized by large intra-abdominal tumors in the ovary and the omentum. During OvCa dissemination, the cancer cells detach from the primary site, which can be the fallopian tube, the ovary, or the peritoneum. Subsequently, the peritoneal fluid carries the OvCa cells to secondary sites of implantation, including the omentum, the most common site of OvCa metastasis. These sites are exclusively organs with a single layer of mesothelial cells covering an underlying stroma composed of extracellular matrices (ECM) and stromal cells (2, 3) . Consequently, OvCa cells must invade through the barrier of mesothelial cells on the peritoneum, omentum, and bowel serosa to effectively form metastases.
Mesothelial cells were originally depicted as a mechanical barrier that must be pushed to the side by tumor cells (4, 5) . In coculture, cancer cells induced human mesothelial cells to retract from the peritoneum and omentum, thereby exposing the underlying ECM (4). Iwanicki and colleagues extended these findings by showing that OvCa spheroids use myosin-generated force to clear mesothelial cells in human mesothelial cell line monolayers (5, 6) . Tumor-induced apoptosis may also be important for mesothelial cell clearance and peritoneal invasion (7) .
However, reports that mesothelial cells may induce the motility of OvCa cells supports a possible tumor-promoting role for these cells during OvCa metastasis. Rieppi et al. revealed that conditioned media (CM) of primary human mesothelial cells induced migration of OvCa cell lines through a gelatin-coated Boyden chamber (8) , and a later paper demonstrated that mesothelial cells promote OvCa adhesion (9) . Collectively, these findings were the first evidence that mesothelial cells actively participate in the establishment of the OvCa metastatic niche. This concept is consistent with the observation that cancer cells recruit local stromal cells to promote and stabilize their growth (10) . The interaction between cancer and stromal cells has primarily been studied in cancerassociated fibroblasts (CAFs), which have been shown to promote almost every aspect of local tumor growth (11) . In the OvCa microenvironment, CAFs (12, 13) and cancer-associated adipocytes (14, 15) promote invasion and metastasis, which indicates that OvCa cells have the capability to recruit various types of stromal cells. It is therefore unlikely that mesothelial cells are simply "bystanders" that must be pushed out of the way by invading OvCa cells in the metastatic process. Rather, it is likely that they are recruited by OvCa cells and reprogrammed to facilitate tumor growth. Indeed, cancer cell CM may stimulate mesothelial cell motility (16, 17) .
Ovarian cancer (OvCa) metastasizes to organs in the abdominal cavity, such as the omentum, which are covered by a single layer of mesothelial cells. Mesothelial cells are generally thought to be "bystanders" to the metastatic process and simply displaced by OvCa cells to access the submesothelial extracellular matrix. Here, using organotypic 3D cultures, we found that primary human mesothelial cells secrete fibronectin in the presence of OvCa cells. Moreover, we evaluated the tumor stroma of 108 human omental metastases and determined that fibronectin was consistently overexpressed in these patients. Blocking fibronectin production in primary mesothelial cells in vitro or in murine models, either genetically (fibronectin 1 floxed mouse model) or via siRNA, decreased adhesion, invasion, proliferation, and metastasis of OvCa cells. Using a coculture model, we determined that OvCa cells secrete TGF-β1, which in turn activates a TGF-β receptor/RAC1/ SMAD-dependent signaling pathway in the mesothelial cells that promotes a mesenchymal phenotype and transcriptional upregulation of fibronectin. Additionally, blocking α 5 or β 1 integrin function with antibodies reduced metastasis in an orthotopic preclinical model of OvCa metastasis. These findings indicate that cancer-associated mesothelial cells promote colonization during the initial steps of OvCa metastasis and suggest that mesothelial cells actively contribute to metastasis.
Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion
showed an increased level of fibronectin in the omental tissue harboring OvCa metastases ( Figure 1C and Supplemental Figure  1C ). In addition, fibronectin was abundant in the ascites of OvCa patients (Supplemental Figure 1D and ref. 19) .
To determine whether the fibronectin expression in metastatic OvCa is of functional significance, ECM was extracted from unfixed benign and tumor transformed omental tissue removed at surgery from separate patients. In the ECM from omental metastasis, fibronectin expression was found to be higher, and multiple cleavage forms of fibronectin were detected ( Figure 1D ). Compared with ECM from normal omentum, 2 OvCa cell lines, HeyA8 and SKOV3ip1, showed increased adhesion and proliferation to the omental ECM extracted from metastatic tumors ( Figure 1E and Supplemental Figure 1E ). Cells bind to fibronectin through specific cell surface integrins, including the fibronectin receptor α 5 β 1 integrin and the vitronectin receptor α v β 3 integrin (21). Adhesion and proliferation of OvCa cells to tumor-derived ECM could be abrogated using blocking antibodies against these integrins as well as an RGD peptide, whereas control IgG, the control RAD peptide, and a β 4 integrin antibody had no inhibitory effect ( Figure  1E and Supplemental Figure 1E ).
Next, we investigated whether early metastasis of OvCa cells to the omentum could be modeled ex vivo with human omental tissue and in vivo in mice. Injection of HeyA8 OvCa cells i.p. induced strong expression of fibronectin in the mouse omentum ( Figure 2A ). Attachment of fluorescently labeled OvCa cells to a piece of human omentum followed by fluorescence-activated cell sorting (FACS) to separate OvCa and omental cells also showed strong protein and RNA induction of fibronectin in the surface cells that interacted with the cancer cells, whereas expression in the cancer cells was unchanged ( Figure 2B) .
The mesothelium covers all organs within the abdominal cavity, including the peritoneum and the omentum. It is composed of a monolayer of mesothelial cells, on top of an ECM interspersed with resting fibroblasts that are responsible for secreting most of the ECM in the basement membrane ( Figure 1B , Supplemental Figure 1B , and refs. 25, 26) . We and others have modeled the mesothelium in a 3D culture (5, 25) using primary human omental fibroblasts and mesothelial cells (Supplemental Figure 2) . Coculture of SKOV3ip1 cells with the organotypic 3D culture induced fibronectin synthesis and matrix assembly ( Figure 2C ). Fibronectin matrix secretion and assembly can be assessed by detecting the conversion of cell-associated, deoxycholic acid (DOC)-soluble fibronectin fibrils into a DOC-insoluble fibril network (22) . Coculture of OvCa cells with the 3D culture for 48 hours induced the secretion of soluble fibronectin in the ECM of the 3D culture and also induced the aggregation of fibronectin as a dense DOCinsoluble matrix ( Figure 2C ). Moreover, binding of inactive fibronectin dimers to integrins on the OvCa cell surface induced a dense fibronectin matrix ( Figure 2D ). These data suggest that binding of OvCa cells to the omentum induces early fibronectin production and matrix assembly, which is functionally important for adhesion, migration, and invasion.
OvCa cells stimulate fibronectin expression in mesothelial cells. Since mesothelial cells are the first cell type to interact with metastasizing OvCa cells (27) , we sought to determine how the interaction between OvCa cells and mesothelial cells results in Increased expression of fibronectin (encoded by FN1), a key component of the ECM, has been detected in OvCa metastases compared with the primary ovarian tumor (14, 18) , and fibronectin is also present in ascites (19) . While multiple integrins bind fibronectin at specific amino acid sequences (i.e., PHSRN and RGD), α 5 β 1 integrin is selective for fibronectin (20) . The binding of integrins to the ECM promotes integrin clustering and subsequently triggers integrin-mediated intracellular signal transduction (21) , while at the same time, integrin receptors mediate fibronectin matrix assembly (22) . Functionally, fibronectin induces adhesion, proliferation, and invasion of tumor cells and contributes to the formation, adhesion, and disaggregation of OvCa spheroids (16, 23, 24) .
Given our previous finding that fibronectin is overexpressed in OvCa metastases (14) , as well as indications that mesothelial cells might communicate with OvCa cells, we hypothesized that OvCa-induced fibronectin expression by mesothelial cells may play a critical role in the early steps of OvCa metastasis. We report here that OvCa cells stimulated mesothelial cells to produce fibronectin through secretion of TGF-β1, thereby activating a TGF-β receptor 1 (TGF-βRI)/RAC1/SMAD-dependent signaling pathway in the mesothelial cells. The activated mesothelial cells promoted metastasis by supporting tumor cell adhesion, invasion, and proliferation.
Results
OvCa cells induce fibronectin production early in metastasis to the human omentum. The most common site of OvCa metastasis in patients with serous high-grade cancers is the omentum. In fact, in mouse models, OvCa cells home to the omentum immediately after i.p. injection (14) . In a previous study, we used a reverse phase protein array to identify protein expression in paired ovarian and omental metastases and found that fibronectin expression was higher in the omental metastasis than in the primary tumor, while other ECM proteins, such as vitronectin, were more highly expressed in the primary tumor (14) . This was confirmed by immunoblot using snap-frozen tissue of the paired samples from the same cohort of patients (Supplemental Figure 1A and Supplemental Methods; supplemental material available online with this article; doi:10.1172/JCI74778DS1). The results were further validated using a tissue microarray (TMA) constructed with tissue from omental metastases from 108 patients with advanced OvCa. In 93% of these patients (100 of 108), fibronectin expression was much stronger in the stromal than in the epithelial cell compartment ( Figure 1A ). To determine whether fibronectin expression is an early or late event during omental/peritoneal metastasis, we identified samples from a small subgroup of women diagnosed with stage IIIA serous-papillary OvCa (FIGO 1988 staging), defined by microscopic disease to the omentum (Supplemental Figure 1B) , which allowed us to study early OvCa metastasis. Immunohistochemical staining showed that fibronectin expression was induced below proliferating metastatic cells that had not yet invaded the basement membrane ( Figure 1B ). Once the tumor invaded, the stroma around the serous tumor islands had very strong fibronectin expression ( Figure 1C in primary human mesothelial cells using siRNA and evaluated adhesion, invasion, and proliferation of 2 OvCa cell lines. Without the fibronectin support from the mesothelial cells, neither of the OvCa cell lines were able to adhere (59% of control), invade (36%), or proliferate (54%) as efficiently ( Figure 4A ). Furthermore, when fibronectin was knocked down in the mesothelial cells that covered a full piece of human omentum, the OvCa cells were again not able to adhere, invade, or proliferate as efficiently as control transfected cells ( Figure 4B ). These experiments were corroborated in vivo using a transgenic mouse model of fibronectin deficiency. Homozygous floxed fibronectin 1 (Fn1) mice (Fn1 fl/fl mice) do not have an obviously abnormal phenotype, and have normal fertility and life spans. However, upon induction of ischemic brain injury, the deletion of Fn1 leads to large brain infarcts, which are, at least in part, due to the absence of the antiapoptotic function of fibronectin (29) . fl/fl mice inhibited OvCa metastasis by 86%. These data suggest that the prometastatic function of fibronectin involves a non-fibronectin-receptormediated factor. On the basis of the combined data in Figures 4 and 5, we propose that mesothelial cell fibronectin expression promotes early OvCa metastasis.
Tumor cells induce fibronectin expression in mesothelial cells through a TGF-βRI/RAC1/SMAD3-dependent signaling pathway.
Analysis of gene expression data from the Australian Ovarian Cancer Study (AOCS) and from the Cancer Genome Atlas (TCGA) OvCa data showed that FN1 mRNA was most highly expressed in the C1 molecular subtype (high stromal response; Supplemental Figure  7A ). When we inhibited SMAD3 using siRNA in mesothelial cells or added a TGF-βRI inhibitor or TGF-βRII antibody to mesothelial cells followed by the addition of SKOV3ip1 CM, fibronectin secretion was impaired ( Figure 7B ), which was paralleled by reduced FN1 mRNA in the mesothelial cells (Supplemental Figure 7A) .
Coculture of OvCa cells with mesothelial cells strongly induced RAC1 activity, while total RAC1 expression was unchanged (Figure 7C and Supplemental Figure 7B ). The increase in RAC1-GTP was specifically observed (by IF) in mesothelial cells after coculture with SKOV3ip1 cells ( Figure 7C ). Inhibition of RAC1 expression in mesothelial cells with either a RAC1 siRNA or the RAC1 inhibitor abrogated FN1 mRNA in cocultured mesothelial cells and fibronectin secretion in OvCa cell CM-stimulated mesothelial cells ( Figure 7D and Supplemental Figure 7A ). Because our findings suggested that both RAC1 and TGF-β1 signaling regulate fibronectin expression, we asked whether TGF-β1 regulates fibronectin through RAC1 signaling. Indeed, the TGF-β1-mediated induction of fibronectin expression in mesothelial cells could be abrogated by blocking RAC1 signaling ( Figure 7E ). Taken together, these data suggest that tumor cells induce EMT in mesothelial cells through TGF-β1 signaling.
Blocking α 5 integrin or β 1 integrin prevents OvCa metastasis. In view of the critical role of fibronectin during early OvCa metastasis, 2 potential clinically applicable fibronectin receptor function blocking antibodies were evaluated in vitro and in vivo. The established OvCa cell lines HeyA8 and SKOV3ip1 were fluorescently labeled and then cultured on the 3D culture with antibodies. Both α 5 integrin (37) and β 1 integrin (38) blocking antibodies prevented Figure 6A ), which is associated with serous high-grade cancer and the poorest survival (31) . Subsequent pathway analysis indicated that the epithelial to mesenchymal transition (EMT) was the second most significant biological pathway that correlated with elevated fibronectin expression in the AOCS and TCGA cohorts (Supplemental Tables 1 and 2 Figure 6E) , and (d) TGF-β1 is highly expressed in omental metastasis (34) . To test this hypothesis, TGF-β1 expression was inhibited in SKOV3ip1 cells using siRNA. CM from these cells induced less fibronectin production in mesothelial cells than did CM from control siRNA-stimulated cells ( Figure 6B and Supplemental Figure  6F ). SKOV3ip1 CM-stimulated mesothelial cells were then treated with an inhibitor of TGF-βRI, an antibody against TGF-βRII, and inhibitors of small G proteins (the downstream TGF-β1 effectors RAC, RAS, and RHO; ref. 35 ). The TGF-βRI inhibitor, the TGF-βRII antibody, and the RAC inhibitor blocked fibronectin secretion by mesothelial cells; however, the RAS and RHO inhibitors had no such effect ( Figure 6C ). Comparably, FN1 mRNA expression testing, ATN-161 (Ac-PHSCN-NH2), a 5-mer capped peptide derived from the fibronectin synergy region, was evaluated in vitro and in vivo. The synergy region of fibronectin is a ligand for α 5 β 1 integrin, which increases the avidity of α 5 β 1 integrin for the fibronectin RGD sequence (19) . The peptide blocked both proliferation and invasion of the established OvCa cell lines HeyA8 and SKOV3ip1 by an average of 29% and 52%, respectively (Supplemental Figure 8A ). To study the in vivo efficacy of ATN-161, we took 2 approaches (37): (a) testing the peptide in a prevention study in vitro adhesion by an average of 60% and invasion and proliferation by an average of 40% ( Figure 8A ). To study the in vivo efficacy of the 2 antibodies, we tested them in a prevention study (treatment the day of and 2 and 4 days after OvCa cell intraovarian injection) that mimicked treatment during initiation of metastasis. Pretreatment of mice with α 5 integrin or β 1 integrin blocking antibodies reduced metastasis number and tumor weight by more than 90% compared with IgG control-treated mice ( Figure  8B ). Finally, the therapeutic effect of a compound now in clinical ponents of the metastatic process (10). However, the role of these cells in the molecular events underlying the early dissemination of abdominally metastasizing tumors remains poorly defined. The peritoneal cavity and the omentum are lined by the mesothelium, a monolayer of mesothelial cells resting on a basement membrane. This tissue functions to maintain serosal integrity and provide a nonadhesive surface that allows smooth bowel movements. It also acts as a permeability barrier, secreting various substances involved in the regulation of peritoneal permeability and local host defense (2) . By testing several stromal cell components using an organotypic 3D model of the human omentum/peritoneum that we developed previously (25, 39), we found here that OvCa cells specifically induced protein expression, mRNA production, and promoter activity of fibronectin in mesothelial cells (Figures 2 and 3) . Conversely, by inhibiting fibronectin expression in the mesothelial cells using siRNA, we were able to reduce adhesion, migration, and invasion in vitro (Figure 4) , and by using an (treatment the day of and 3 and 5 days after OvCa cell i.p. injection) that mimicked treatment of microscopic disease, and (b) treating advanced tumors in an intervention study (treatment 3 times per week starting on day 7 after OvCa cell i.p. injection), a design that mimicked treatment of advanced disease. Pretreatment of mice with ATN-161 in the prevention study reduced metastasis number by 52% and tumor weight by 70% compared with control-treated mice (Supplemental Figure 8B) . Surprisingly, the peptide also reduced metastatic spread by 66% and tumor weight by 65% in the intervention study, when the drug was given after the establishment of tumors (Supplemental Figure 8C) . Taken together, these data suggest that inhibiting the interaction of integrins with fibronectin blocks both early and late steps of OvCa metastasis.
Discussion
In recent years, we have come to understand that stromal cells in the tumor microenvironment and the ECM are important com- moting almost every aspect of tumor progression through activation of mitogenic signaling. In addition, it has known antiapoptotic functions (29) , promotes angiogenesis (21), and promotes the recruitment of regulatory T cells (46) . In invasive ovarian tumors, fibronectin expression is found in the ECM, the submesothelial basement membrane of omental metastasis (Figure 1) , and in ascites (19) and is associated with an adverse clinical prognosis (47) . Moreover, the cleavage of fibronectin into small fragments by MMP-2 has been found to enhance the adhesion of OvCa cells to the peritoneal surface (39) . Taken together, these data clearly indicate that fibronectin levels and proteolytic cleavage forms promote the aggressiveness of OvCa cells. The concept presented here, that the fibronectin secreted by mesothelial cells is important for the metastatic process of OvCa cells, should have considerable relevance when selecting clinically useful targeted therapies. We found that functionally blocking both α 5 integrin and β 1 integrin function inhibited the initial metastasis of OvCa cells and reduced the initiation and growth of metastatic tumors (Figure 8 and refs. 48, 49) . Furthermore, ATN-161, a short fibronectin peptide binding to α 5 β 1 and α v β 3 integrins, blocked the initial metastasis of OvCa cells and inhibited the growth of established tumors (Supplemental Figure 8) . ATN-161 was previously tested in preclinical models of breast and lung cancer (34) and in a clinical phase I study that resulted in patients with solid tumors showing stable disease (36) . Our present data suggest that maintenance therapy aimed at blocking the interaction of fibronectin with the fibronectin receptor α 5 β 1 integrin after the end of adjuvant chemotherapy might delay tumor recurrence and should be considered for further clinical testing. In addition, knocking down fibronectin in mesothelial cells was significantly more efficient in inhibiting OvCa metastasis than solely blocking α 5 β 1 integrin, which suggests that other integrin and nonintegrin fibronectin receptors contribute to fibronectin-mediated metastasis within the abdominal cavity.
On the basis of our combined data, we propose that the interaction of OvCa cells with the mesothelium is an important functional predeterminant of tumor metastasis and growth (Figure 8C) . Is it possible, however, to reconcile the observation that OvCa cells displaced mesothelial cells and induced their apoptosis with the finding that mesothelial cells promoted cancer cell metastasis? It may be that the very initial interaction of OvCa cells with mesothelial cells leads to displacement of some of the mesothelial cells, allowing the OvCa cells to adhere directly to the submesothelial ECM (6, 27, 32) . The data presented here indicate that after establishing their initial foothold, OvCa cells actively recruit and activate adjacent mesothelial cells. Therefore, the mesothelial cells play a key supporting role in establishing the first metastatic colony on the omentum/peritoneum, acting as cancer-associated mesothelial cells.
Methods
Further information can be found in Supplemental Methods.
Reagents. Collagen I (rat tail) and fibronectin were purchased from BD Biosciences. The human OvCa cell lines, SKOV3ip1 and inducible floxed fibronectin mouse model, we reduced metastasis in vivo ( Figure 5 ). These results suggest that OvCa cells recruit mesothelial cells, inducing them to secrete fibronectin to help the cancer cells establish the initial metastatic colony ( Figure 8C) . Indeed, the behavior of the primary mesothelial cells we studied suggested that they become associated with cancer cells (i.e., cancer-associated mesothelial cells [CAMs] ) in a manner analogous to CAFs (40) and cancer-associated adipocytes (15, 41) . This supports a broader concept that cancer cells are able to recruit a variety of cell types in the microenvironment to create an activated tumor stroma that supports growth and metastasis. More than 20% of OvCas present as stage IV with pleural effusion, but without radiologic evidence of intrapulmonary nodules. Although we did not study pleural metastasis, it is interesting to note that the pleural cavity is also lined by a single layer of mesothelial cells. This raises the possibility that a similar mechanism contributes to colonization of the pleura in OvCa.
In the presence of OvCa cells secreting TGF-β1, mesothelial cells underwent EMT, upregulating vimentin and downregulating E-cadherin. Their phenotype then changed from a cobblestone pattern to one of spindle-like cells resembling fibroblasts (Figures 6 and 7) . Secretion of fibronectin is a well-known mesenchymal marker that was previously used to confirm EMT in mesothelial cells (2, 42) . In mesothelial cells cocultured with OvCa cells, TGF-β1 bound to the TGF-βRI and activated a RAC1/ SMAD-dependent signaling pathway that strongly induced the transcriptional upregulation of fibronectin (Figures 6 and 7) , thus promoting the metastatic cascade. A similar mechanism has also been described for keratinocytes, in which TGF-β1 downregulates E-cadherin and upregulates a RAC-dependent signaling pathway (43, 44) . This is consistent with our present results that RAC1 activity was upregulated when mesothelial cells and OvCa cells were cocultured.
Activation of an EMT program, a general physiological response of the mesothelium to stress, is a phenomenon reported during peritoneal dialysis and peritoneal inflammation. Peritoneal irritation caused by peritoneal dialysis induces mesothelial cells to transition from an epithelial to a mesenchymal phenotype, a process mediated by TGF-β1 (33) . Chronic peritoneal dialysis induces peritoneal fibrosis, which coincides with the EMT of mesothelial cells and the loss of peritoneal membrane integrity and, consequently, the loss of the ability of the membrane to act as a filter during peritoneal dialysis (2) . That mesothelial cells react to both peritoneal dialysis and metastasis with EMT implies that the response of mesothelial cells to cancer cells is not tumor cell specific, but is a generalized reaction of the peritoneum to irritants. Mesothelial cells (45) secrete plasminogen activator inhibitors (PAIs), urokinase (uPA), and VEGF upon local stress (e.g., dialysis and infection). While this has not been directly studied in cancer, it is probable that mesothelial cell secretion of these factors supports metastasis in a manner similar to that described here for their secretion of fibronectin.
Availability of fibronectin to the cancer cells is a critical component for metastasis. This is evidenced by a significant reduction in metastasis or in the ability of cancer cells to invade if fibronectin is knocked out in the peritoneal microenvironment (Figures 4 and 5) . Fibronectin has a well-established role in cancer metastasis, pro-jci.org Volume 124 Number 10 October 2014
14,000 g for 20 minutes, and supernatant was collected. The concentration and sizes of ECMs isolated were analyzed using BCA protein concentration assay and SDS-PAGE. The protocol was adapted from a method previously described by Abberton et al. (59) . Additionally, the ECM secreted by mesothelial cells was analyzed. Briefly, cells were washed 3 times with PBS and floated off of plate in 0.2N NH 4 OH. The remaining ECMs were washed 3 times with PBS, collected, and analyzed using SDS-PAGE. The protocol was adapted from a previously described method (60) .
qRT-PCR. After coculture of GFP-labeled OvCa cells with full human omentum, the 3D omental culture, or primary human mesothelial cells, cells were sorted by FACS in PBS (39) . This procedure separated labeled OvCa cells from mesothelial cells and/or fibroblasts after their coculture. TRIzol reagent was used to isolate RNA according to the manufacturer's instructions (Invitrogen). cDNA was synthesized using the Applied Biosystems cDNA archive kit. After reverse transcription, real-time PCR was performed using a Prism7500 TaqMan PCR detector (Applied Biosystems) with predesigned and validated TaqMan probes for FN1, CDH1 (encoding E-cadherin), and VIM (encoding vimentin) in conjunction with GAPDH for normalization (Applied Biosystems) (58) . The reactions were run in triplicate. Relative levels of mRNA expression were calculated using the 2 -ΔΔCt method (61) . Differences between treatments were evaluated using unpaired, 2-tailed Student's t test.
Immunoblot analysis. For analysis of cellular fibronectin, tissue or cells after FACS were lysed, and equal quantities of protein were added to each blot. For analysis of secreted ECM, equal volumes of ECM lysate were added to each blot. For analysis of tumor ECM, equal quantities of protein were added to each blot. Proteins were resolved by SDS-PAGE and transferred to nitrocellulose, and immunoblot analysis was performed (58) . The following antibodies were applied overnight at 4°C: anti-fibronectin (1:2,000 dilution); anti-phospho-SMAD2/3 (1:1,000), anti-E-cadherin (1:2,000), anti-vimentin (1:2,000), anti-GAPDH (1:2,000), mouse anti-actin (1:50,000). Blots were than incubated with secondary horseradish peroxidase-conjugated IgG and visualized with enhanced chemiluminescence reagents.
Ex vivo full human omentum culture. For omental cultures, a fresh piece of full human omentum was cut into 8-mm pieces (equivalent weights) (14) . All omental pieces were placed in a 24-well dish (1 piece/well). For the adhesion assay, full human omentum pieces were transfected with in vivo fibronectin or control siRNA 24 hours prior to coculture with 1 × 10 6 fluorescently labeled SKOV3ip1 cells.
After incubation at 37°C for 4 hours, omental pieces were washed 3 times in PBS, digested in 5% NP-40 for 30 minutes at 37°C, and scraped with a metal spatula. All cells removed during digestion were placed in a 24-well plate, and the total fluorescent intensity per well was quantified. Adhesion assays were run in quadruplicate. For coculture assays, full human omentum pieces were cultured with 1 × 10 6 SKOV3ip1 cells. After incubation at 37°C for 48 hours, omental pieces were digested in 0.2% trypsin-EDTA for 5 minutes at 37°C and scraped with a metal spatula. The trypsin was neutralized, and collected cells were pelleted. For analysis of fibronectin expression and production, GFP-labeled SKOV3ip1 cells and omental surface cells were sorted by FACS. Primary omental cells and 3D omental culture. Primary human mesothelial cells and fibroblasts were isolated from the omentum, and purification was verified by vimentin, keratin 8, and prolyl-hydroxylase
The cell lines were validated by short tandem repeat DNA fingerprinting using the AmpFlSTR Identifier kit (Applied Biosystems) and compared with known American Type Culture Collection fingerprints, the Cell Line Integrated Molecular Authentication database (CLIMA), and the University of Texas MD Anderson Cancer Center fingerprint database. Negative control, fibronectin, in vivo fibronectin, and vitronectin siRNA were purchased from Ambion Inc.; SMAD3 and TGF-β1 siGENOME siRNA were purchased from Dharmacon. TGF-β1 was from Gibco. The TGF-βRI kinase inhibitor I (catalog no. 616451) (51), TGF-βRI kinase inhibitor II (catalog no. 616452) (52) , and RHO kinase inhibitor (catalog no. 555552) (53) were from Calbiochem. The RAS signaling activity inhibitor (catalog no. 10010501) (54) was from Cayman Chemical. The RAC-GEF interaction inhibitor (catalog no. 2161) was from Tocris Bioscience (55) . The TGF-βRII antibody (catalog no. AF-241-NA) was from R&D Systems (56) . The β 1 integrin (clone P5D2) antibody was purchased from Santa Cruz. The fibronectin (clone 568), β 4 integrin (clone ASC-3), α V β 3 integrin (clone LM609), and α 5 integrin (clone P1D6) antibodies were purchased from Millipore. The β 1 integrin (OS2966) antibody was provided by OncoSynergy. The mouse α 5 integrin antibody (clone 339.1) was provided by Facet Biotech Corp. The nonspecific IgG was from Chrome Pure, Jackson ImmunoResearch. Anti-SMAD2/3 (catalog no. 610842) and anti-E-cadherin (catalog no. 610181) antibodies were from BD Transduction Laboratories. Anti-vimentin (clone V9) antibody was purchased from Dako Cytomation. Anti-actin, anti-pSMAD2/3 (clone D6G10), and anti-GAPDH (clone 14C10) antibodies were from Cell Signaling Technology. Ad5CMVCre-eGFP and Ad5CMV-eGFP were purchased from University of Missouri.
TMA and immunohistochemistry. TMA cores (n = 2) of omental metastases from 108 patients with serous papillary OvCa were collected (Supplemental Table 3 ). The patients were selected for the TMAs by a gynecologic pathologist. Clinical and histopathologic information was collected and updated as previously reported (57) . TMA slides were deparaffinized and incubated with anti-fibronectin (SigmaAldrich) at 1:400 dilution as previously described (25, 39) . Slides were stained using the Envision avidin-biotin-free detection system and counterstained with hematoxylin. Quantification and localization of fibronectin protein expression was performed using Aperio ImageScope and Spectrum software. Tumor-and stroma-specific classifiers were developed using a Spectrum analysis program with Genie capabilities (Supplemental Figure 9) . The intensity of DAB staining was determined in tumor-or stroma-specific regions of the tumor cores. Differences between tumor and stroma fibronectin expression were evaluated using a Wilcoxon rank test comparing the 2 treatments.
ECM isolation. ECM was isolated from primary human omentum obtained from patients with benign disease and from omental metastases from OvCa patients as previously described (58) . Briefly, fresh tissue was cut (1-2 mm thickness), suspended in dispase solution (2 mg/g tissue), and incubated for 2 hours at 4°C. The tissue sections were rubbed over a cell sieve (250 μm), and the remaining matrices were homogenized in high salt buffer (0.05M Tris pH 7.4, 3.4M NaCl, 4 μM N-ethylmaleimide) containing protease inhibitors (0.001 mg/ml pepstatin, 0.01 mg/ml aprotonin, 2 mM orthovanadate, and 1 mM PMSF). The matrices were centrifuged 3 times at 7,000 g for 15 minutes, and the supernatant was discarded. The pellet was incubated in 2M urea buffer (0.15M NaCl, 0.05M Tris pH 7.4) at 1 ml buffer/g tissue rotating for 48 hours at 4°C. The solubilized ECMs were centrifuged at jci. and infected with Ad-Cre or Ad-Cont. Adhesion, invasion, and proliferation of ID8 cells were examined on the adenovirus-infected peritoneal surface cells, as described above. The adenovirus infection was efficient (>92%; infection at MOI 50), as observed with eGFP expression, and did not reduce viability (MOI <100). Recombination of floxed Fn1 was verified by allele-specific PCR (see below).
immunohistochemistry (25, 39) . The 3D omental culture system was assembled by plating 4,000 human primary fibroblasts per well plus 0.5 μg collagen type I. 4 hours later, human primary mesothelial cells were added at a density of 20,000 cells in 0.33 cm 2 .
Adhesion assay. Omental ECM (0.5 μg), tumor ECM (0.5 μg), or 20,000 primary human mesothelial cells were used to coat a 96-well dish (0.33 cm 2 ), and a 1-hour adhesion assay was performed with 40,000 fluorescently labeled OvCa cells (39) . Cells were treated with mouse IgG, β 1 integrin, α 5 integrin, α v β 3 integrin, or β 4 integrin antibodies (20 μg/ml) at the time of cell plating. Differences between treatments were evaluated using unpaired, 2-tailed Student's t test. Invasion assay. 50,000 fluorescently labeled OvCa cells were plated on each well of a 24-well transwell plate (0.33 cm 2 ) that was precoated with 20 μg omental ECM, precoated with 20 μg tumor ECM, or contained 20 μg collagen type I with 20,000 primary human mesothelial cells. Cells were treated with mouse IgG, β 1 integrin, α 5 integrin, α v β 3 integrin, or β 4 integrin antibodies (20 μg/ml) at the time of cell plating. The invasion assays were performed as previously described (39) . Differences between treatments were evaluated using unpaired, 2-tailed Student's t test.
IF. GFP-labeled SKOV3ip1 cells were added to a culture of primary human mesothelial cells or fibronectin-coated (100 μg) glass coverslips for 48 hours (25) . The cells were fixed with 4% paraformaldehyde in PBS for 30 minutes, and IF was performed. Primary antibodies against fibronectin (1:400 dilution) and secondary antibodies (goat anti-rabbit Alexa Fluor 645, 1:200 dilution; Invitrogen) were used. Intracellular fibronectin was analyzed using Triton-X detergent in buffers (0.1%), while extracellular fibronectin was analyzed using buffers lacking detergents. The Triton-X detergent permeabilizes the cell membrane, allowing for intracellular fibronectin detection while washing away extracellular fibronectin. Nuclear counterstain was performed with Hoechst. Imaging was performed using a Zeiss LSM510 confocal microscope.
DOC solubility assay. The assay was based on the insolubility of fibronectin matrix in 2% DOC detergent (62) . Cell pellets were lysed in DOC lysis buffer (2% sodium DOC, 20 mM Tris-HCl pH 8.8, 2 mM PMSF, 2 mM EDTA, 2 mM iodoacetic acid, 2 mM N-ethylmaleimide). Lysates were centrifuged to separate DOC-insoluble matrix from DOC-soluble material containing cell-associated and intracellular fibronectin. The DOC-insoluble fibronectin was solubilized in a buffer containing 1% SDS (20 mM Tris-HCl pH 8.8, 2 mM PMSF). The DOC-soluble and -insoluble fractions were resolved by SDS-PAGE, transferred to nitrocellulose, and analyzed by immunoblotting.
Inhibition experiments. Human OvCa cell lines SKOV3ip1 and HeyA8 were added to a confluent culture of primary human mesothelial cells and treated with RAC inhibitor (5 μm), RAS inhibitor (25 μm), RHO inhibitor (10 μm), TGF-βRI inhibitors (10 μm), or anti-TGF-βRII (8 μg/ml) neutralizing antibody. Fibronectin production and secretion was analyzed 48 and 72 hours later, respectively. Fibronectin, SMAD3, TGF-βRII, and control siRNA constructs were transfected into 2 × 10 6 primary human mesothelial cells 18 hours prior to coculture with SKOV3ip1 cells. SKOV3ip1 cells were transfected with TGF-β1 or control siRNA constructs using Lipofectamine Transfection Reagent (Invitrogen). The cells recovered in full growth media (10% fetal bovine serum) for 18 hours, and serum-free media was added. SKOV3ip1 cell CM was collected after 48 hours and concentrated (10×) using a spin column with 3-μm filter (Millipore). For the in vivo study, 2.5 × 10 4 HeyA8 cells were mixed with mouse IgG (control) or α 5 integrin or β 1 integrin antibody (10 μg/ml), and 10 μl was injected into the ovaries of athymic nude mice. At 2 and 4 days after injection, mouse IgG or α 5 integrin or β 1 integrin antibody in PBS (10 mg/kg/d) was administered i.p. At 28 days after injection, mice were sacrificed (10 per group). The number of tumor colonies was counted, and the tumor was weighed (57) . Statistics. Adhesion (n = 5) and invasion (n = 3) assays were performed and at least 3 independent experiments conducted. Mean and SEM are reported. Significance of differences was determined by 2-tailed independent (unpaired) t test; a P value less than 0.05 was considered significant.
Study approval. Specimens of human omentum were obtained from patients undergoing surgery for benign conditions, and tumor samples from OvCa patients undergoing surgery, at the University of Chicago. All human specimens were obtained in accordance with a protocol approved by the University of Chicago IRB, and subjects provided informed consent. All animal procedures were approved by
